Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Combines Synopsis Solicitation- iPSC Differentiati

Active
75N98026Q00878Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health, through its Office of the Director and Office of Acquisitions, is seeking to award a firm fixed-price contract on a non-competitive basis to Oxford StemTech Ltd of Oxford, UK, for scientific support services related to the quality control of induced pluripotent stem cells and the generation and characterization of organoids using a subset of these cell lines. This acquisition is conducted under streamlined commercial item procedures outlined in FAR Subpart 12.6 and is not expected to exceed the simplified acquisition threshold, with authority derived from FAR 12.603, 41 U.S.C. 1901, and FAR 6.302-3(a)(2)(ii). The solicitation, identified by number 75N98026Q00878, serves as both the notice of intent and the sole solicitation document, eliminating the need for a separate formal request. The contract is classified under NAICS code 541714 and is being procured without competition due to the unique technical capabilities required and the specialized nature of the services. The response deadline for proposals is July 31, 2026, at 6:00 p.m. Eastern Time, with the posting date listed as July 27, 2026. All submissions must be directed to the designated point of contact, John R. Johnson, reachable via email at johnsonjr@mail.nih.gov, with the contract performance to be carried out in Bethesda, Maryland. The contract will be executed under the authority of the Department of Health and Human Services, and no set-asides or small business preferences are applicable. The offering entity, Oxford StemTech Ltd, has been identified as the only qualified source capable of delivering the required services, justifying the non-competitive approach under the specified regulatory exceptions.

General Info

NIH awards non-competitive contract to Oxford StemTech Ltd for stem cell and organoid services in Bethesda, Maryland.

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

MD

Set-Aside

NONE

Documents

(1)

Sol_75N98026Q00878.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
Contacts1 person available
OfficeBETHESDA, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Olao
View Agency Profile
Office AddressBETHESDA, MD, 20892, USA

Full Description

Show more
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued.

(ii) The solicitation number is 75N98026Q00878/PCA-NIMH-02470. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable).
This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii).

The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm fix-price award on a non-competitive basis to Oxford StemTech Ltd The Oxford Science Park Hayakawa Building Edmund Hally Road Oxford, UK to acquire scientific support services for the quality control of Induced Pluripotent Stem Cells (iPSCs) and use of a subset of these iPSC lines for generation and characterization of organoids.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Humanized Antibody Library Screening and Transferrin Receptor DevelopmentThe contract involves the customized screening of a humanized antibody library to develop a functional transferrin receptor, encompassing molecular design, in vitro selection, and optimization of binding affinity and specificity. The work requires advanced techniques in antibody engineering to identify and refine candidates capable of high-affinity, selective interaction with the transferrin receptor, with the goal of producing a therapeutically viable candidate. The scope includes iterative cycles of library screening, functional characterization, and structural optimization to enhance target binding while minimizing off-target interactions, ensuring the final product meets stringent performance benchmarks. This subcontract is issued under the NAICS code 541714 for research and development in the biological sciences and is associated with the National Institutes of Health through the Department of Health and Human Services. The place of performance is in Bethesda, Maryland, with a deadline for proposals set for July 31, 2026. The contract is expected to support biomedical innovation targeting receptor-mediated delivery systems and requires expertise in molecular biology, high-throughput screening, and protein engineering. No specific set-aside provisions are indicated, and the work is open to qualified subcontractors capable of delivering scalable, data-driven antibody development solutions within the defined timeline.
National Institutes Of Health Olao

POSTED

3 days ago

DEADLINE

in 4 days
View Details
NAICS: 541714
New
Federal
Develop and Validate Transferrin ReceptorThe National Institutes of Health, under the Department of Health and Human Services, has issued a presolicitation notice for the development and validation of a transferrin receptor, identified by solicitation number 75N98026Q00866. This opportunity is open for responses until July 31, 2026, and was posted on July 24, 2026, with no set-aside provisions applied, making it open to all eligible entities. The work will be performed in Bethesda, Maryland, and falls under the NAICS code 541714, which corresponds to research and development in the physical, engineering, and life sciences. The primary point of contact for inquiries is Towanda Daniels, reachable via email at danielt@mail.nih.gov. Interested parties are directed to the official SAM.gov workspace link for further details and submission guidelines. The contract aims to support advanced scientific research focused on the transferrin receptor, likely to advance biomedical applications or therapeutic technologies. All proposals must adhere to the requirements outlined in the notice of intent, and submissions should be prepared with consideration for the technical scope, timeline, and performance standards expected by the NIH Office of Laboratory Animal Welfare. The contract is structured to enable innovation in molecular biology or drug delivery systems involving receptor targeting, with performance expected within the confines of federal research protocols and compliance standards.
National Institutes Of Health Olao

POSTED

3 days ago

DEADLINE

in 4 days
View Details
NAICS: 541714
New
Federal
Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreakThe Food and Drug Administration is planning to award a sole source firm-fixed price purchase order to The University of Liverpool under simplified acquisition procedures for the sequencing of Bundibugyo virus disease during the 2026 outbreak, relying on FAR Part 6.103-1 which permits non-competitive procurement when only one responsible source exists. This action falls under the NAICS code 541714 for Research and Development in Biotechnology and is not open for competitive bidding, as the FDA has determined that The University of Liverpool is the only entity with the necessary expertise and capacity to meet the technical requirements for this highly specific viral sequencing effort. The contract is intended to support bioanalytical method development and sample analysis by providing critical reagents and reference standards for quantifying CYP enzyme substrates and metabolites in hepatocyte experiments during the outbreak response. Responses to this notice must be submitted by Ryan Alexander at ryan.alexander@fda.hhs.gov no later than 5:00 pm on July 29, 2026, and must include a detailed capability statement for any other organization seeking consideration, though the government retains full discretion to determine whether a response justifies competitive solicitation. The procurement is not a request for competitive quotes, and no set-aside is being applied. The contract will be administered from the FDA’s office in Rockville, Maryland, with performance primarily occurring in Liverpool, England, and the solicitation number is OC-2026-135667, issued on July 24, 2026.
Food And Drug Administration

POSTED

3 days ago

DEADLINE

in 2 days
View Details
NAICS: 541714
New
Federal
Procurement of lateral flow (LFA) strips for the rapid HIV nucleic acid diagnostic testThe Centers for Disease Control and Prevention is soliciting bids for the procurement of 4,000 lateral flow strips intended for use in a rapid HIV nucleic acid diagnostic test under a firm-fixed-price contract, issued as a Request for Quote in accordance with FAR Subpart 12 for commercial items. The solicitation number is 75D30126Q79099, with a performance period of August 1, 2026, to December 31, 2026, and an option to extend services for up to six additional months. Proposals must be submitted electronically to Eugene Gutierrez at zvm0@cdc.gov no later than 3:00 P.M. Eastern Standard Time on Friday, July 24, 2026, with no telephonic or paper submissions accepted. The place of performance is the CDC facility at 1600 Clifton Road, Building 17, Atlanta, GA 30329-4018. Offerors must be registered in the System for Award Management at the time of submission and are required to comply with all applicable FAR clauses, including 52.212-1 and 52.212-4, along with deviations such as those addressing trafficking in persons, contractor employee whistleblower rights, sustainable products and services, Buy American Act alternatives for Israeli and Korean end products, and prohibitions on unauthorized information sharing. Technical evaluation is the predominant factor in award, emphasizing experience with biomedical devices, FDA approval processes, and prior work with lateral flow technology, with price considered secondary. The contractor must deliver 200 prototype strips and 4,000 final units meeting stringent performance standards: ≤0.5% false positive rate and ≤1% false negative rate using CDC’s LAMP reaction, and must ensure full compatibility with CDC’s mass production protocols. All deliverables must conform to Section 508 accessibility requirements, including WCAG 2.0 Level AA, and vendors must provide a Voluntary Product Accessibility Template or HHS conformance checklist. The contract imposes strict security and confidentiality obligations, including mandatory non-disclosure agreements for all employees accessing sensitive information, identification protocols to distinguish contractor personnel from government staff, and prohibitions against retaining or disseminating federal records or Privacy Act data. Subcontractors must be bound by the same requirements, and all payments must be processed via the Treasury’s Invoice Processing Platform using an ACH Vendor Enrollment
CDC Office Of Acquisition Services

POSTED

3 days ago

DEADLINE

in 2 days
View Details
NAICS: 541714
New
Federal
Battlefield Pain Management – AnalgesicThis solicitation, identified as HT942726RE009 and titled Battlefield Pain Management – Analgesic, is issued under the Defense Health Agency’s prototype Other Transaction Authority (pOTA) authority pursuant to 10 U.S.C. § 4022 to acquire a single-use analgesic product for battlefield use, with the goal of achieving FDA approval for acute moderate to severe pain. The product must be administered rapidly and easily, possess a small physical profile for individual carry, and remain stable without refrigeration across extreme temperature conditions ranging from -25°C to 45°C, with a required shelf life of 2–3 years at controlled room temperature. It must comply with USP <659> packaging standards and meet stringent quality system requirements under 21 CFR Part 820, including labeling control and documentation of chemical composition. The product must be classified as DEA Schedule II or higher and may utilize a device-based delivery method such as a nasal spray or autoinjector, with physiological constraints limiting blood pressure and heart rate decreases to no more than 20% and preserving blood clotting capacity with minimal airway impact. The project spans an estimated eight years divided into three objectives—Chemistry, Manufacturing, and Controls (CMC) and stability studies over three years, non-clinical enabling studies over two years, and clinical trials and human factors testing over three years, contingent on successful completion of prior phases. Proposals must be submitted in three distinct volumes—Technical, Management, and Administrative and Cost—and adhere to strict formatting requirements including searchable PDF format, page limits for specified sections, and inclusion of a Microsoft Project file for the schedule. The submission window was extended from July 30, 2026, to August 14, 2026, with questions due by July 10, 2026, and must be sent via email to designated points of contact. Proposals must demonstrate at least one pass/fail gate condition: participation of a nontraditional defense contractor or nonprofit research institute to a significant extent; all significant participants being small businesses or nontraditional contractors; or cost-sharing from non-federal sources accounting for at least one-third of the total project cost. Evaluation focuses on technical approach, management strategy, and cost structure, with award determined by the most advantageous proposal. The agreement is not subject to the FAR or DFARS, except for referenced clauses such as DFARS 252.232-
Defense Health Agency

POSTED

4 days ago

DEADLINE

in 18 days
View Details
NAICS: 541714
New
Federal
Development of Light-Responsive Artificial Cells using Plant-Based Photoreceptor SystemsThe United States Army Corps of Engineers Engineer Research and Development Center Construction Engineering Research Laboratory is seeking to develop light-responsive artificial cells by integrating plant-derived UVR8 photoreceptor systems into synthetic biology platforms, using high-throughput protein engineering and AI-assisted structural refinement to create programmable, pseudo-living systems activated by environmental light stimuli. The project aims to advance foundational science in synthetic biology by leveraging Bioconscientia, LLC’s uniquely specialized expertise in UVR8 photoreceptor technology, which enables precise sensing of UV-B light in a manner unmatched by other entities. Due to the highly specialized nature of the required research and Bioconscientia’s irreplaceable knowledge of existing experimental data and technical pathways, the government intends to award a sole-source contract to this vendor under RFO FAR 12.102(a), with an anticipated award date of September 30, 2026. This presolicitation notice, issued under FAR Part 5.101(a) with solicitation number W9132T26QA015 and NAICS code 541714, does not constitute a formal request for proposals or a competitive procurement, nor is it a set-aside. Interested parties may submit capability statements to CERL-CT-QUOTES@USACE.ARMY.MIL by July 31, 2026, to be reviewed for potential technical equivalency, but submission does not guarantee a change to the government’s acquisition strategy. The government retains full discretion to proceed with sole-source award regardless of responses received. All work will be performed in Champaign, Illinois, and the primary point of contact for submissions is Lurline L. Simmons, with Andrea J. Thomas serving as the contracting officer. No telephone inquiries will be accepted.
W2R2 Construction Engrg Labor

POSTED

5 days ago

DEADLINE

in 4 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

NAICS: 811210
New
Federal
Combines Synopsis Solicitation- Maintenance AgreemThe National Institutes of Health, through the Office of the Director’s Office of Acquisitions, is issuing a non-competitive combined synopsis and solicitation to award a firm fixed-price contract to Hamamatsu for the maintenance, service, and warranty support of NanoZoomer Whole Slide Image Scanners used in NIH laboratories. This acquisition is conducted under FAR Subpart 12.6 and utilizes streamlined procedures for commercial items, with no expectation of exceeding the simplified acquisition threshold. The solicitation does not seek competitive bids and is authorized under FAR 6.302-3(a)(2)(ii) and 41 U.S.C. 1901, allowing for direct award to Hamamatsu based on its unique capability to service this specific equipment. The contract will provide ongoing technical expertise and comprehensive service agreements to ensure uninterrupted operation of the NanoZoomer scanners across NIH facilities. The solicitation number is 75N98026Q00883, and proposals must be submitted by July 31, 2026, at 6:00 p.m. EST. The contract is being managed by the Office of Acquisitions at NIH in Bethesda, Maryland, with Johnson, John R. as the primary point of contact. Although the place of performance is unspecified, the work will support NIH laboratory operations nationwide. The North American Industry Classification System code for this acquisition is 811210, indicating it falls under office machinery and equipment repair and maintenance. There is no set-aside type, and the entire process is designed for expedited non-competitive award based on the singular technical expertise required to maintain the proprietary NanoZoomer scanner systems.
Electronic and Precision Equipment Repair and Maintenance

POSTED

about 10 hours ago

DEADLINE

in 4 days
View Details
NAICS: 541713
New
Federal
Oxford Nanopore Technologies promethION 2 integrated long-read sequencerThe contract is for the procurement of an Oxford Nanopore Technologies PromethION 2 integrated long-read sequencer, a next-generation sequencing platform designed to deliver highly informative, real-time genomic and transcriptomic data. Unlike conventional next-generation sequencing technologies, this instrument enables simultaneous whole genome and transcriptome sequencing while detecting base modifications, facilitating unified multi-omics analysis with unprecedented depth and speed. The system is intended for high-impact research applications requiring comprehensive molecular profiling and real-time data integration, positioning it as a critical tool for advanced biological discovery. The solicitation, numbered 75N98026Q00877, was posted by the National Institutes of Health under the Department of Health and Human Services, with the contracting office located in Bethesda, Maryland. The opportunity is classified as a presolicitation with no set-aside designation, and it falls under NAICS code 541713 for research and development in the physical, engineering, and life sciences. The primary point of contact is Vishnuvajjala Hanumanth Rao, reachable via email at vishnuh@mail.nih.gov. Responses are due by August 5, 2026, and performance will be carried out at the agency’s facility in Bethesda, with all equipment to be deployed at the specified location.
Research and Development in Nanotechnology

POSTED

about 10 hours ago

DEADLINE

in 9 days
View Details
NAICS: 325413
New
Federal
Combined Synopsis Solicitation- Acquire 32-sample The National Institutes of Health, through the Department of Health and Human Services, is soliciting proposals under a non-competitive combined synopsis and solicitation for the acquisition of a 32-sample product, identified by solicitation number 75N98026Q00881. This procurement is conducted under FAR Part 12.603 as a streamlined process for commercial items and falls below the simplified acquisition threshold, utilizing statutory authority under 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii) to justify the absence of full and open competition. The solicitation is issued as a Notice of Intent and serves as the only formal request for proposals, with no additional written solicitation to follow. Proposals must be submitted by the deadline of August 3, 2026, at 6:00 p.m. Eastern Time, following the posting date of July 27, 2026. The contracting activity is managed by the Office of Acquisition and Logistics Operations in Bethesda, Maryland, with the NAICS code 325413 indicating the product relates to pharmaceutical and medicine manufacturing. The primary point of contact for inquiries is Cassie M. Runner, reachable via email at cassie.runner@nih.gov or phone at 301-480-8827. The place of performance has not been specified, but the contract award will be directed toward a commercial supplier capable of meeting requirements without competitive bidding, in alignment with the streamlined procedures and statutory exceptions under federal acquisition regulations. All responses must comply with the terms outlined in the combined synopsis, and no further documentation will be issued beyond this notice.
In-Vitro Diagnostic Substance Manufacturing

POSTED

about 10 hours ago

DEADLINE

in 7 days
View Details